ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
36.67
1.13%
US Tech 100
19,854.00
0.04%
S&P 500
5,667.20
0.64%
US Dollar vs CAD
1.36721
-0.05%
Bitcoin
64,943.30
0.14%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ImmunoGen Inc (IMGN)

  7. ImmunoGen Inc (IMGN) News

IMGN

ImmunoGen (IMGN)

ImmunoGen Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IMGN
DateTimeSourceHeadlineSymbolCompany
07/11/20125:30AMBusiness WireImmunoGen, Inc. Initiates Phase I Trial of IMGN853 in Ovarian Cancer & Other Solid Tumors Over-Expressing Its Folate Receptor...NASDAQ:IMGNImmunoGen Inc
07/02/20129:05AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IMGNImmunoGen Inc
06/19/20129:57AMEdgar (US Regulatory)Current report filing (8-K)NASDAQ:IMGNImmunoGen Inc
06/03/201211:01PMBusiness WireImmunoGen, Inc. Announces Presentation of New Clinical Data for SAR3419NASDAQ:IMGNImmunoGen Inc
06/03/20127:30PMBusiness WireImmunoGen, Inc. Announces Development of Trastuzumab Emtansine for Early Stage HER2-Positive Breast CancerNASDAQ:IMGNImmunoGen Inc
06/02/201211:01PMBusiness WireImmunoGen, Inc. Announces Results from Trastuzumab Emtansine (T-DM1) EMILIA Phase III TrialNASDAQ:IMGNImmunoGen Inc
05/16/20125:30AMBusiness WireImmunoGen, Inc. Announces Presentations at 2012 ASCO Annual Meeting on Product Candidates with the Company’s TAP TechnologyNASDAQ:IMGNImmunoGen Inc
05/10/20121:14PMEdgar (US Regulatory)Quarterly Report (10-Q)NASDAQ:IMGNImmunoGen Inc
05/08/20122:17PMEdgar (US Regulatory)Confidential Treatment Order (CT ORDER)NASDAQ:IMGNImmunoGen Inc
05/08/20122:17PMEdgar (US Regulatory)Confidential Treatment Order (CT ORDER)NASDAQ:IMGNImmunoGen Inc
05/08/20125:30AMBusiness WireImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor ConferencesNASDAQ:IMGNImmunoGen Inc
04/27/20126:56AMEdgar (US Regulatory)Current report filing (8-K)NASDAQ:IMGNImmunoGen Inc
04/27/20125:30AMBusiness WireImmunoGen, Inc. Reports Third Quarter Fiscal Year 2012 Financial Results and Provides Quarterly UpdateNASDAQ:IMGNImmunoGen Inc
04/18/20123:15PMBusiness WireImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2012 Financial ResultsNASDAQ:IMGNImmunoGen Inc
04/17/20125:30AMBusiness WireImmunoGen, Inc. Announces the IND Is Now Active for Its Folate-Receptor Targeting Anticancer Compound, IMGN853NASDAQ:IMGNImmunoGen Inc
04/17/20125:15AMBusiness WireImmunoGen, Inc. Initiates Phase I Trial in Non-Hodgkin’s Lymphoma with Its Novel IMGN529 Anticancer CompoundNASDAQ:IMGNImmunoGen Inc
04/03/20129:12AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IMGNImmunoGen Inc
03/30/20122:11PMDow Jones News3rd UPDATE: Roche Breast Cancer Drug Shows Late-Stage SuccessNASDAQ:IMGNImmunoGen Inc
03/30/20126:30AMDow Jones NewsUPDATE: New Roche Breast Cancer Drug Shows Late Stage Trial SuccessNASDAQ:IMGNImmunoGen Inc
03/30/20125:01AMBusiness WireImmunoGen, Inc. Announces Conference Call at 8:00 am ET March 30, 2012 to Discuss Today’s Favorable Announcements about Tra...NASDAQ:IMGNImmunoGen Inc
03/30/20125:00AMBusiness WireImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 Product CandidateNASDAQ:IMGNImmunoGen Inc
03/30/20124:15AMZacksRoche's Cancer Drug Moves Forward - Analyst BlogNASDAQ:IMGNImmunoGen Inc
03/30/201212:01AMBusiness WireImmunoGen, Inc. Announces Positive Results in Trastuzumab Emtansine (T-DM1) EMILIA Phase III TrialNASDAQ:IMGNImmunoGen Inc
03/02/20122:00PMBusiness WireImmunoGen, Inc. Announces Webcast of Presentation at the Cowen 32nd Annual Health Care ConferenceNASDAQ:IMGNImmunoGen Inc
02/16/20128:27AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IMGNImmunoGen Inc
02/14/201210:23AMEdgar (US Regulatory)Schedule 13GNASDAQ:IMGNImmunoGen Inc
02/14/20128:16AMEdgar (US Regulatory)Amended Statement of Ownership (SC 13G/A)NASDAQ:IMGNImmunoGen Inc
02/13/201212:32PMEdgar (US Regulatory)Amended Statement of Ownership (SC 13G/A)NASDAQ:IMGNImmunoGen Inc
02/13/201212:10PMEdgar (US Regulatory)Amended Statement of Ownership (SC 13G/A)NASDAQ:IMGNImmunoGen Inc
02/07/20124:08PMEdgar (US Regulatory)Amended Statement of Ownership (SC 13G/A)NASDAQ:IMGNImmunoGen Inc
 Showing the most relevant articles for your search:NASDAQ:IMGN

Your Recent History

USOTC
AXXA
Exxe (PK)
USOTC
UBQU
Ubiquitech Software (PK)
USOTC
RNVA
Rennova Health (PK)
USOTC
MGON
Megola (PK)
NASDAQ
COOP
Mr Cooper
NASDAQ
FFIE
Faraday Future Intellige...
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
ENZC
Enzolytics (PK)
USOTC
FNMA
Fannie Mae (QB)
NASDAQ
NB
NioCorp Developments
AMEX
SPY
SPDR S&P 500
USOTC
WDLF
Decentral Life (PK)
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
RONN
Ronn Motor (PK)
USOTC
KEGS
1812 Brewing (PK)
USOTC
HIRU
Hiru (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved